The impact of eligibility for maintenance immunotherapy on prognosis in patients with unresectable or metastatic urothelial carcinoma
Abstract Objectives To investigate the eligibility for maintenance immunotherapy and its impact on the prognosis of advanced urothelial carcinoma treated with first‐line chemotherapy, as the selection biases of the eligible population in the JAVELIN Bladder 100 trial remain unclear. Methods We retro...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-03-01
|
| Series: | BJUI Compass |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/bco2.119 |
| _version_ | 1819278201519603712 |
|---|---|
| author | Kai Ozaki Shingo Hatakeyama Toshikazu Tanaka Daisuke Noro Noriko Tokui Hirotaka Horiguchi Yoshiharu Okuyama Naoki Fujita Teppei Okamoto Akiko Okamoto Yuichiro Suzuki Hayato Yamamoto Takahiro Yoneyama Yasuhiro Hashimoto Chikara Ohyama |
| author_facet | Kai Ozaki Shingo Hatakeyama Toshikazu Tanaka Daisuke Noro Noriko Tokui Hirotaka Horiguchi Yoshiharu Okuyama Naoki Fujita Teppei Okamoto Akiko Okamoto Yuichiro Suzuki Hayato Yamamoto Takahiro Yoneyama Yasuhiro Hashimoto Chikara Ohyama |
| author_sort | Kai Ozaki |
| collection | DOAJ |
| description | Abstract Objectives To investigate the eligibility for maintenance immunotherapy and its impact on the prognosis of advanced urothelial carcinoma treated with first‐line chemotherapy, as the selection biases of the eligible population in the JAVELIN Bladder 100 trial remain unclear. Methods We retrospectively evaluated 213 patients (median age, 71 years) with unresectable locally advanced or metastatic urothelial carcinoma treated with platinum‐based first‐line chemotherapy between May 2003 and April 2021. The patients were categorized into the following two groups: progressive disease (PD) within four cycles (trial ineligible group) and non‐PD within four cycles (trial eligible group). The primary outcomes were the estimated proportion of trial eligible patients for maintenance immunotherapy. The secondary outcomes were the comparison of the overall survival in the trial eligible and ineligible groups and the impact of radiologic response at the second cycle on the fourth cycle. Results Among the 213 patients, 81 (38%) were included in the trial eligible group. The trial eligible group had a significantly longer overall survival than the trial ineligible group (P < 0.001). Of 166 patients who had no PD within two cycles, 85 (51%) patients experienced PD within four cycles. Patients with a complete response or partial response at the second cycle had a significantly lower rate of PD at the fourth cycle (42%) than those with stable disease at the second cycle (59%, P = 0.031). Conclusion We observed 38% of the trial eligible population. Overall survival was significantly different between the trial eligible and ineligible groups. |
| first_indexed | 2024-12-24T00:08:15Z |
| format | Article |
| id | doaj.art-857c205233624511ba6c913939492daf |
| institution | Directory Open Access Journal |
| issn | 2688-4526 |
| language | English |
| last_indexed | 2024-12-24T00:08:15Z |
| publishDate | 2022-03-01 |
| publisher | Wiley |
| record_format | Article |
| series | BJUI Compass |
| spelling | doaj.art-857c205233624511ba6c913939492daf2022-12-21T17:24:57ZengWileyBJUI Compass2688-45262022-03-013213914510.1002/bco2.119The impact of eligibility for maintenance immunotherapy on prognosis in patients with unresectable or metastatic urothelial carcinomaKai Ozaki0Shingo Hatakeyama1Toshikazu Tanaka2Daisuke Noro3Noriko Tokui4Hirotaka Horiguchi5Yoshiharu Okuyama6Naoki Fujita7Teppei Okamoto8Akiko Okamoto9Yuichiro Suzuki10Hayato Yamamoto11Takahiro Yoneyama12Yasuhiro Hashimoto13Chikara Ohyama14Department of Urology Hirosaki University Graduate School of Medicine Hirosaki JapanDepartment of Urology Hirosaki University Graduate School of Medicine Hirosaki JapanDepartment of Urology Aomori Prefectural Central Hospital Aomori JapanDepartment of Urology Mutsu General Hospital Mutsu JapanDepartment of Urology Odate Municipal Hospital Odate JapanDepartment of Urology Hirosaki University Graduate School of Medicine Hirosaki JapanDepartment of Urology Hirosaki University Graduate School of Medicine Hirosaki JapanDepartment of Urology Hirosaki University Graduate School of Medicine Hirosaki JapanDepartment of Urology Hirosaki University Graduate School of Medicine Hirosaki JapanDepartment of Urology Oyokyo Kidney Research Institute Hirosaki JapanDepartment of Urology Aomori City Hospital Aomori JapanDepartment of Urology Hirosaki University Graduate School of Medicine Hirosaki JapanDepartment of Advanced Transplant and Regenerative Medicine Hirosaki University Graduate School of Medicine Hirosaki JapanDepartment of Urology Hirosaki University Graduate School of Medicine Hirosaki JapanDepartment of Urology Hirosaki University Graduate School of Medicine Hirosaki JapanAbstract Objectives To investigate the eligibility for maintenance immunotherapy and its impact on the prognosis of advanced urothelial carcinoma treated with first‐line chemotherapy, as the selection biases of the eligible population in the JAVELIN Bladder 100 trial remain unclear. Methods We retrospectively evaluated 213 patients (median age, 71 years) with unresectable locally advanced or metastatic urothelial carcinoma treated with platinum‐based first‐line chemotherapy between May 2003 and April 2021. The patients were categorized into the following two groups: progressive disease (PD) within four cycles (trial ineligible group) and non‐PD within four cycles (trial eligible group). The primary outcomes were the estimated proportion of trial eligible patients for maintenance immunotherapy. The secondary outcomes were the comparison of the overall survival in the trial eligible and ineligible groups and the impact of radiologic response at the second cycle on the fourth cycle. Results Among the 213 patients, 81 (38%) were included in the trial eligible group. The trial eligible group had a significantly longer overall survival than the trial ineligible group (P < 0.001). Of 166 patients who had no PD within two cycles, 85 (51%) patients experienced PD within four cycles. Patients with a complete response or partial response at the second cycle had a significantly lower rate of PD at the fourth cycle (42%) than those with stable disease at the second cycle (59%, P = 0.031). Conclusion We observed 38% of the trial eligible population. Overall survival was significantly different between the trial eligible and ineligible groups.https://doi.org/10.1002/bco2.119chemotherapymaintenance immunotherapyprognosisradiological responseurothelial carcinoma |
| spellingShingle | Kai Ozaki Shingo Hatakeyama Toshikazu Tanaka Daisuke Noro Noriko Tokui Hirotaka Horiguchi Yoshiharu Okuyama Naoki Fujita Teppei Okamoto Akiko Okamoto Yuichiro Suzuki Hayato Yamamoto Takahiro Yoneyama Yasuhiro Hashimoto Chikara Ohyama The impact of eligibility for maintenance immunotherapy on prognosis in patients with unresectable or metastatic urothelial carcinoma BJUI Compass chemotherapy maintenance immunotherapy prognosis radiological response urothelial carcinoma |
| title | The impact of eligibility for maintenance immunotherapy on prognosis in patients with unresectable or metastatic urothelial carcinoma |
| title_full | The impact of eligibility for maintenance immunotherapy on prognosis in patients with unresectable or metastatic urothelial carcinoma |
| title_fullStr | The impact of eligibility for maintenance immunotherapy on prognosis in patients with unresectable or metastatic urothelial carcinoma |
| title_full_unstemmed | The impact of eligibility for maintenance immunotherapy on prognosis in patients with unresectable or metastatic urothelial carcinoma |
| title_short | The impact of eligibility for maintenance immunotherapy on prognosis in patients with unresectable or metastatic urothelial carcinoma |
| title_sort | impact of eligibility for maintenance immunotherapy on prognosis in patients with unresectable or metastatic urothelial carcinoma |
| topic | chemotherapy maintenance immunotherapy prognosis radiological response urothelial carcinoma |
| url | https://doi.org/10.1002/bco2.119 |
| work_keys_str_mv | AT kaiozaki theimpactofeligibilityformaintenanceimmunotherapyonprognosisinpatientswithunresectableormetastaticurothelialcarcinoma AT shingohatakeyama theimpactofeligibilityformaintenanceimmunotherapyonprognosisinpatientswithunresectableormetastaticurothelialcarcinoma AT toshikazutanaka theimpactofeligibilityformaintenanceimmunotherapyonprognosisinpatientswithunresectableormetastaticurothelialcarcinoma AT daisukenoro theimpactofeligibilityformaintenanceimmunotherapyonprognosisinpatientswithunresectableormetastaticurothelialcarcinoma AT norikotokui theimpactofeligibilityformaintenanceimmunotherapyonprognosisinpatientswithunresectableormetastaticurothelialcarcinoma AT hirotakahoriguchi theimpactofeligibilityformaintenanceimmunotherapyonprognosisinpatientswithunresectableormetastaticurothelialcarcinoma AT yoshiharuokuyama theimpactofeligibilityformaintenanceimmunotherapyonprognosisinpatientswithunresectableormetastaticurothelialcarcinoma AT naokifujita theimpactofeligibilityformaintenanceimmunotherapyonprognosisinpatientswithunresectableormetastaticurothelialcarcinoma AT teppeiokamoto theimpactofeligibilityformaintenanceimmunotherapyonprognosisinpatientswithunresectableormetastaticurothelialcarcinoma AT akikookamoto theimpactofeligibilityformaintenanceimmunotherapyonprognosisinpatientswithunresectableormetastaticurothelialcarcinoma AT yuichirosuzuki theimpactofeligibilityformaintenanceimmunotherapyonprognosisinpatientswithunresectableormetastaticurothelialcarcinoma AT hayatoyamamoto theimpactofeligibilityformaintenanceimmunotherapyonprognosisinpatientswithunresectableormetastaticurothelialcarcinoma AT takahiroyoneyama theimpactofeligibilityformaintenanceimmunotherapyonprognosisinpatientswithunresectableormetastaticurothelialcarcinoma AT yasuhirohashimoto theimpactofeligibilityformaintenanceimmunotherapyonprognosisinpatientswithunresectableormetastaticurothelialcarcinoma AT chikaraohyama theimpactofeligibilityformaintenanceimmunotherapyonprognosisinpatientswithunresectableormetastaticurothelialcarcinoma AT kaiozaki impactofeligibilityformaintenanceimmunotherapyonprognosisinpatientswithunresectableormetastaticurothelialcarcinoma AT shingohatakeyama impactofeligibilityformaintenanceimmunotherapyonprognosisinpatientswithunresectableormetastaticurothelialcarcinoma AT toshikazutanaka impactofeligibilityformaintenanceimmunotherapyonprognosisinpatientswithunresectableormetastaticurothelialcarcinoma AT daisukenoro impactofeligibilityformaintenanceimmunotherapyonprognosisinpatientswithunresectableormetastaticurothelialcarcinoma AT norikotokui impactofeligibilityformaintenanceimmunotherapyonprognosisinpatientswithunresectableormetastaticurothelialcarcinoma AT hirotakahoriguchi impactofeligibilityformaintenanceimmunotherapyonprognosisinpatientswithunresectableormetastaticurothelialcarcinoma AT yoshiharuokuyama impactofeligibilityformaintenanceimmunotherapyonprognosisinpatientswithunresectableormetastaticurothelialcarcinoma AT naokifujita impactofeligibilityformaintenanceimmunotherapyonprognosisinpatientswithunresectableormetastaticurothelialcarcinoma AT teppeiokamoto impactofeligibilityformaintenanceimmunotherapyonprognosisinpatientswithunresectableormetastaticurothelialcarcinoma AT akikookamoto impactofeligibilityformaintenanceimmunotherapyonprognosisinpatientswithunresectableormetastaticurothelialcarcinoma AT yuichirosuzuki impactofeligibilityformaintenanceimmunotherapyonprognosisinpatientswithunresectableormetastaticurothelialcarcinoma AT hayatoyamamoto impactofeligibilityformaintenanceimmunotherapyonprognosisinpatientswithunresectableormetastaticurothelialcarcinoma AT takahiroyoneyama impactofeligibilityformaintenanceimmunotherapyonprognosisinpatientswithunresectableormetastaticurothelialcarcinoma AT yasuhirohashimoto impactofeligibilityformaintenanceimmunotherapyonprognosisinpatientswithunresectableormetastaticurothelialcarcinoma AT chikaraohyama impactofeligibilityformaintenanceimmunotherapyonprognosisinpatientswithunresectableormetastaticurothelialcarcinoma |